Dianthus Therapeutics (DNTH) Income from Continuing Operations (2017 - 2025)

Dianthus Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 36630000.0 for Q3 2025.

• In Q3 2025, Income from Continuing Operations fell 31.78% year-over-year to 36630000.0; the TTM figure through Sep 2025 stood at 125466000.0 (down 78.3% YoY), while the FY2024 annual figure was 84499000.0, down 94.65% from the prior year.
• Income from Continuing Operations was 36630000.0 for Q3 2025 at Dianthus Therapeutics, down from 31524000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 7077000.0 in Q1 2023 to a low of 36630000.0 in Q3 2025.
• Historically, Income from Continuing Operations has averaged 18840947.37 across 5 years, with a median of 17427000.0 in 2021.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 69.16% in 2023, then tumbled 165.66% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 19292000.0 in 2021, then jumped by 47.89% to 10053000.0 in 2022, then fell by 4.57% to 10512000.0 in 2023, then sank by 165.66% to 27926000.0 in 2024, then sank by 31.17% to 36630000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 36630000.0 (Q3 2025), 31524000.0 (Q2 2025), and 29386000.0 (Q1 2025), per Business Quant data.